European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 97

Food and Drug Administration Safety Patients Leads 97

PM360

NOVEMBER 12, 2024

We’re gaining a richer understanding of the brain’s complex inner workings, and today’s innovations reveal the vast, untapped potential of science and technology to transform the lives of patients and their families. Regarding leadership, my guiding principle has always been to do what’s right for patients and your people.

Food and Drug Administration 52

Food and Drug Administration Healthcare Provider Healthcare Healthcare 52

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.

Side effects 40

Side effects Marketing Pharmaceutical Sales 40